Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Thalidomide
Drug ID BADD_D02192
Description A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem]
Indications and Usage For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
Marketing Status approved; investigational; withdrawn
ATC Code L04AX02
DrugBank ID DB01041
KEGG ID D00754
MeSH ID D013792
PubChem ID 5426
TTD Drug ID D0U7GK
NDC Product Code 17205-205; 59572-215; 68554-0011; 82991-205; 59572-220; 17337-0301; 59572-210; 59572-205; 63818-0424
UNII 4Z8R6ORS6L
Synonyms Thalidomide | Sedoval | Thalomid
Chemical Information
Molecular Formula C13H10N2O4
CAS Registry Number 50-35-1
SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.0010.005594%
Abdominal pain07.01.05.002--
Acne23.02.01.001---
Acquired immunodeficiency syndrome10.03.03.001; 11.05.17.007---
Acute leukaemia01.10.02.001; 16.01.02.001---
Acute lymphocytic leukaemia01.10.01.001; 16.01.01.0010.000482%-
Acute myeloid leukaemia01.10.05.001; 16.01.05.0010.000844%-
Acute respiratory distress syndrome10.02.01.067; 22.01.03.001; 24.03.02.0340.000723%
Adrenal disorder05.01.03.0010.000241%-
Ageusia07.14.03.003; 17.02.07.0010.003231%-
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.001---
Alanine aminotransferase increased13.03.04.005--
Albuminuria20.02.01.001---
Alopecia23.02.02.001--
Altered state of consciousness17.02.04.001; 19.07.01.003---
Amblyopia06.02.01.001---
Amenorrhoea05.05.01.002; 21.01.02.001--
Amnesia17.03.02.001; 19.20.01.001--
Amyloidosis10.02.05.0010.001302%-
Anaemia01.03.02.0010.006751%
Anaemia macrocytic01.03.02.002; 14.12.01.002---
Anaemia megaloblastic01.03.02.003; 14.12.01.003---
Angina pectoris02.02.02.002; 24.04.04.002--
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Anosmia17.04.04.001; 22.04.03.0060.001471%
Anxiety19.06.02.002--
Aortic stenosis24.04.01.0010.000362%-
Aphasia17.02.03.001; 19.21.01.0010.000723%
Aphthous ulcer07.05.06.0020.001061%-
The 1th Page    1 2 3 4 5    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene